Wed, 15 Feb 2017 12:00:00 EST Resistant Starch, Gut Bacteria and Diabetes Conditions: Diabetes Mellitus, Type 2; Pre Diabetes Intervention: Dietary Supplement: SymbioIntest Sponsors: University of Hohenheim; Institut für Mikroökologie GmbH Recruiting - verified February 2017
Wed, 08 Feb 2017 12:00:00 EST Red Raspberry Polyphenols on Gut Microbiome Conditions: Healthy Subjects; Pre-diabetes Interventions: Dietary Supplement: Raspberry and fructooligosaccharide; Dietary Supplement: Raspberry Sponsor: Institute for Food Safety and Health, United States Not yet recruiting - verified February 2017
FDA (Food and Drug Administration) press releases. FDA makes sure of the safety of all medicines which can be injected, breathed in, rubbed in and swallowed, in the United States of America.
Latest Top (10) News
FDA approves new psoriasis drug The U.S. Food and Drug Administration today approved Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis. Siliq is administered as an injection.
Wed, 15 Feb 2017 17:47:00 -0500 FDA approves drug to treat Duchenne muscular dystrophy The U.S. Food and Drug Administration today approved Emflaza (deflazacort) tablets and oral suspension to treat patients age 5 years and older with Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes progressive muscle deterioration and weakness. Emflaza is a corticosteroid that works by decreasing inflammation and reducing the activity of the immune system.
Fri, 03 Feb 2017 16:32:00 -0500 FDA confirms elevated levels of belladonna in certain homeopathic teething products The U.S. Food and Drug Administration announced today that its laboratory analysis found inconsistent amounts of belladonna, a toxic substance, in certain homeopathic teething tablets, sometimes far exceeding the amount claimed on the label. The agency is warning consumers that homeopathic teething tablets containing belladonna pose an unnecessary risk to infants and children and urges consumers not to use these products.
Thu, 19 Jan 2017 09:03:00 -0500 Statement from FDA Commissioner Robert Califf, M.D. announcing new draft guidances on medical product communications We recognize that there is a high level of interest regarding FDA’s views on communications about medical products. We are committed to an ongoing dialogue with industry and other stakeholders, and, when needed, providing guidance to clarify the agency’s thinking on these issues. Today, the FDA released two separate draft guidances that will each help provide clarity for medical product companies, as well as other interested parties, on FDA’s current thinking and recommendations for a few different types of communications about medical products.
Wed, 18 Jan 2017 09:24:00 -0500 FDA and EPA issue final fish consumption advice Today, the U.S. Food and Drug Administration and the U.S. Environmental Protection Agency issued final advice regarding fish consumption. This advice is geared toward helping women who are pregnant or may become pregnant – as well as breastfeeding mothers and parents of young children – make informed choices when it comes to fish that are healthy and safe to eat. (This advice refers to fish and shellfish collectively as “fish.”)
Wed, 18 Jan 2017 09:04:00 -0500 FDA approves first drug for spinal muscular atrophy The U.S. Food and Drug Administration today approved Spinraza (nusinersen), the first drug approved to treat children and adults with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement. Spinraza is an injection administered into the fluid surrounding the spinal cord.
Fri, 23 Dec 2016 16:39:00 -0500
Diabetes news from the American Diabetes Association
Latest Top (5) News
Diabetes news from the National Institutes of Health Diabetes Educators.
Latest Top (10) News
All content and pictures (c) MJoTA.org 2007-2017, may only be used with written permission from the publisher and named owner of the image. All maps and flags from Wikipedia unless otherwise stated. Do not copy and repost pictures or articles unless Dr Susanna and the author has given you permission. You may print and frame pictures or articles for your personal use.
Communicate with Dr Susanna on Facebook, email email@example.com; mail PO Box 381, Haddonfield NJ 08033; telephone 01-609-792-1571.